Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 1999 June;43(2) > The Quarterly Journal of Nuclear Medicine 1999 June;43(2):159-62

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

  RADIOPHARMACOLOGY


The Quarterly Journal of Nuclear Medicine 1999 June;43(2):159-62

Copyright © 2000 EDIZIONI MINERVA MEDICA

lingua: Inglese

Vascular tar­get­ing ­with ­phage pep­tide librar­ies

Pasqualini R.

From the La Jolla Cancer Research Center The Burnham Institute, La Jolla, CA (USA)


FULL TEXT  


We ­have devel­oped an in ­vivo selec­tion ­system in ­which ­phage ­capable of selec­tive hom­ing to dif­fer­ent tis­sues are recov­ered ­from a ­phage dis­play pep­tide ­library fol­low­ing intra­ve­nous admin­is­tra­tion. Using ­this strat­e­gy, we ­have iso­lat­ed sev­er­al ­organ and ­tumor-hom­ing pep­tides. We ­have ­shown ­that ­each of ­those pep­tides ­binds to dif­fer­ent recep­tors ­that are selec­tive­ly ­expressed on the vas­cu­la­ture of the tar­get tis­sue. The ­tumor-hom­ing pep­tides ­bind to recep­tors ­that are upreg­u­lat­ed in ­tumor angio­gen­ic vas­cu­la­ture. Targeted deliv­ery of dox­o­ru­bi­cin to angio­gen­ic vas­cu­la­ture ­using ­these pep­tides in ani­mal mod­els ­decreased tox­ic­ity and ­increased the ther­a­peu­tic effi­ca­cy of the ­drug. Vascular tar­get­ing may facil­i­tate the devel­op­ment of oth­er treat­ment strat­e­gies ­that ­rely on inhi­bi­tion of angio­gen­e­sis and ­lead to advanc­es in can­cer treat­ment. Our tech­nol­o­gy is ­also like­ly to ­extend the poten­tial for tar­get­ing of ­drugs, ­genes, and radio­nu­clides in the con­text of ­many dis­eas­es.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail